New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
10:44 EDTJAZZFDA warns against use of Xyrem with alcohol, CNS depressant drugs
The FDA is reminding healthcare professionals and patients that the combined use of Xyrem (JAZZ) with alcohol or central nervous system depressant drugs can markedly impair consciousness and may lead to severe breathing problems. The use of alcohol with Xyrem is a new contraindication added to the Xyrem label, which already contraindicates its use with insomnia drugs. The use of Xyrem with other CNS depressant drugs such as opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, general anesthetics, and muscle relaxants should generally be avoided. FDA recently evaluated reports of patients who died while taking Xyrem along with alcohol or other CNS depressants. The cause of these deaths is not clear because the reports contained incomplete information and did not adequately address confounding factor. Given some of the circumstances noted in the deaths, however, FDA determined that the recommendations in the Xyrem drug label should be strengthened to more strongly remind healthcare professionals and patients of the risks when using Xyrem with CNS depressant drugs or alcohol. Reference Link
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
11:59 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry discusses the strengths and weaknesses of TEVA’s preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and the perspectives on recent updates in the Jazz Pharmaceuticals' Xyrem patent case on an Analyst/Industry conference call to be held on July 27 at 11 am.
July 20, 2015
10:26 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals / Generics Analyst Gerberry, along with MEDACorp Specialists Michael Belliveau, PhD and Shashank Upadhye, JD, discuss the strengths and weaknesses of TEVA's preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and perspectives on recent updates in the JAZZ Xyrem patent case on an Analyst/Industry conference call to be held on July 22 at 2 pm.
July 17, 2015
08:38 EDTJAZZLeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use